BioCryst Pharmaceuticals, Inc.
8.115USD
-0.6900 (-7.84%)
Computing valuation metrics…
Valuation
P/E (TTM)
—
P/E (Forward)
8.63x
EV/EBITDA
6.31x
EV/Revenue
2.91x
P/S (TTM)
2.20x
P/B
—
FCF Yield
18.01%
Dividend Yield
0.00%
Gross Margin
97.78%
Operating Margin
-33.29%
Net Margin
-40.90%
Peer Comparison — Drug Manufacturers - Specialty & Generic
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| BCRXBioCryst Pharmaceuticals, Inc. | $2.07B | — | 6.31x | 18.01% | 33.61% | 0.00% |
| TEVATeva Pharmaceutical Industries Limited | $42.84B | 61.27x | 13.14x | 5.18% | -0.80% | — |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $30.29B |
| 11.96x |
| 9.31x |
| 6.66% |
| -0.20% |
| 2.88% |
| VTRSViatris Inc. | $18.95B | — | 7.27x | 14.13% | 4.90% | 2.89% |
| HIMSHims & Hers Health, Inc. | $6.51B | — | — | 13.05% | 38.20% | — |
| LQDALiquidia Corporation | $6.19B | 49.37x | 35.09x | 1.20% | 1842.70% | — |
| KNSAKiniksa Pharmaceuticals International, plc | $6.13B | 79.31x | 53.88x | 2.06% | 55.40% | — |
| AMLXAmylyx Pharmaceuticals, Inc. | $3.61B | — | — | -2.14% | — | — |
| BHCBausch Health Companies Inc. | $2.30B | — | 5.71x | 62.23% | 12.70% | — |